Crizotinib, a 1st generation ALK inhibitor, has been reported to have potency in in vitro studies with neuroblastoma cell lines [31], and it has been tested in a Phase I clinical trial for the treatment of pediatric solid tumors [32]. Here, ALK is linked to neuroblastoma.